Premium
Acute tumour lysis syndrome: a case in AL amyloidosis
Author(s) -
Akasheh Marwan S.,
Chang Chi P.,
Vesole David H.
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01719.x
Subject(s) - al amyloidosis , melphalan , medicine , amyloidosis , plasma cell dyscrasia , tumor lysis syndrome , multiple myeloma , chemotherapy , dyscrasia , stem cell , autologous stem cell transplantation , oncology , pathology , plasma cell , immunology , immunoglobulin light chain , biology , antibody , genetics
Tumour lysis syndrome (TLS) in plasma cell dyscrasias is extremely rare. TLS has been described in eight cases of multiple myeloma undergoing high‐dose therapy with autologous stem cell transplant (ASCT). Recently, clinical trials of intensive chemotherapy followed by autologous or allogeneic stem cell support has been shown to offer potential benefit in AL (amyloid light‐chain) amyloidosis. TLS in primary AL amyloidosis in this setting has not been previously reported. We report a case of TLS in a patient with AL amyloidosis which developed after high‐dose melphalan chemotherapy supported by ASCT.